Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?

PURPOSE OF REVIEW: Antagonists of mu-opioid receptor role in cancer progression remains to be elucidated. The objective of this review was to summarize the available evidence on antagonists of mu-opioid receptor effect on tumor progression and prognosis in different types of cancers and an evaluatio...

Full description

Bibliographic Details
Authors: Belltall, A, Mazzinari, G, Diaz-Cambronero, O, Eroles, P, Navarro, MPA
Format: article
Status:Published version
Publication Date:2022
Country:España
Institution:INCLIVA
Repository:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p16603
Online Access:https://incliva.portalinvestigacion.com/publicaciones/16603
Access Level:Open access
Keyword:Cancer
Cancer growth
Low-dose naltrexone
Methylnaltrexone
Mu-opioid receptor (MOR)
Naltrexone
Opioid growth factor (OGF)
Opioid growth factor receptor (OGFr)
PAMORAs
Peripheral antagonists of mu-opioid receptor
Tumor progression
id ES_7ecb326e09495d8dde4bf67c688ab80d
oai_identifier_str oai:incliva.fundanetsuite.com:p16603
network_acronym_str ES
network_name_str España
repository_id_str
spelling Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?Belltall, AMazzinari, GDiaz-Cambronero, OEroles, PNavarro, MPACancerCancer growthLow-dose naltrexoneMethylnaltrexoneMu-opioid receptor (MOR)NaltrexoneOpioid growth factor (OGF)Opioid growth factor receptor (OGFr)PAMORAsPeripheral antagonists of mu-opioid receptorTumor progressionPURPOSE OF REVIEW: Antagonists of mu-opioid receptor role in cancer progression remains to be elucidated. The objective of this review was to summarize the available evidence on antagonists of mu-opioid receptor effect on tumor progression and prognosis in different types of cancers and an evaluation of the available findings on their mechanism of action. RECENT FINDINGS: We have found studies related to methylnaltrexone (MNTX) and naltrexone (NTX) usage in cancer outcomes-related setting. We found consistent preclinical evidence of a potential action of MNTX and NTX on cancer growth and spread mediated mainly by effect on the opioid growth factor receptor (OGFr) axis, which results in depressed cell replication. However, clinical results are scarce and limited to poor-quality evidence. Further high-quality studies are warranted to study antagonists of mu-opioid receptor role as a therapeutic option in different types of cancer, especially in patients where the classical treatment causes unacceptable side effects.SPRINGER2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/16603Current Oncology ReportsISSN: 15233790ISSNe: 15346269reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p166032026-06-07T16:35:31Z
dc.title.none.fl_str_mv Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
title Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
spellingShingle Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
Belltall, A
Cancer
Cancer growth
Low-dose naltrexone
Methylnaltrexone
Mu-opioid receptor (MOR)
Naltrexone
Opioid growth factor (OGF)
Opioid growth factor receptor (OGFr)
PAMORAs
Peripheral antagonists of mu-opioid receptor
Tumor progression
title_short Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
title_full Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
title_fullStr Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
title_full_unstemmed Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
title_sort Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
dc.creator.none.fl_str_mv Belltall, A
Mazzinari, G
Diaz-Cambronero, O
Eroles, P
Navarro, MPA
author Belltall, A
author_facet Belltall, A
Mazzinari, G
Diaz-Cambronero, O
Eroles, P
Navarro, MPA
author_role author
author2 Mazzinari, G
Diaz-Cambronero, O
Eroles, P
Navarro, MPA
author2_role author
author
author
author
dc.subject.none.fl_str_mv Cancer
Cancer growth
Low-dose naltrexone
Methylnaltrexone
Mu-opioid receptor (MOR)
Naltrexone
Opioid growth factor (OGF)
Opioid growth factor receptor (OGFr)
PAMORAs
Peripheral antagonists of mu-opioid receptor
Tumor progression
topic Cancer
Cancer growth
Low-dose naltrexone
Methylnaltrexone
Mu-opioid receptor (MOR)
Naltrexone
Opioid growth factor (OGF)
Opioid growth factor receptor (OGFr)
PAMORAs
Peripheral antagonists of mu-opioid receptor
Tumor progression
description PURPOSE OF REVIEW: Antagonists of mu-opioid receptor role in cancer progression remains to be elucidated. The objective of this review was to summarize the available evidence on antagonists of mu-opioid receptor effect on tumor progression and prognosis in different types of cancers and an evaluation of the available findings on their mechanism of action. RECENT FINDINGS: We have found studies related to methylnaltrexone (MNTX) and naltrexone (NTX) usage in cancer outcomes-related setting. We found consistent preclinical evidence of a potential action of MNTX and NTX on cancer growth and spread mediated mainly by effect on the opioid growth factor receptor (OGFr) axis, which results in depressed cell replication. However, clinical results are scarce and limited to poor-quality evidence. Further high-quality studies are warranted to study antagonists of mu-opioid receptor role as a therapeutic option in different types of cancer, especially in patients where the classical treatment causes unacceptable side effects.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/16603
url https://incliva.portalinvestigacion.com/publicaciones/16603
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER
publisher.none.fl_str_mv SPRINGER
dc.source.none.fl_str_mv Current Oncology Reports
ISSN: 15233790
ISSNe: 15346269
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411776189169664
score 15,81155

Similar Items